pany. Drs. MacConell and Okerson are employees  and shareholders of Amylin Pharmaceuticals, Inc.  REFERENCES  1. Triplitt CL. New technologies and therapies in the man-  agement of diabetes. AmJManag Care. 2007;13(Suppl 2):  547-554.  2. Byetta (exenatide) injections [prescribing information].  San Diego, Califi Amylin Pharmaceuticals, Inc.; 2008. http://pi.lilly.com/us/byetta-pi.pdf. Accessed June 26,  2008.  3. BuseJB, Henry RR, HanJ, et al, forthe Exenatide-113 Clini-  cal Study Group. Effects ofexenatide (exendin-4) on glyce-  mic control over 30 weeks in sulfonylurea-treated patients  with Wpe 2 diabetes. Diabetes Care. 2004;27:2628-2635.  4. DeFronzo IRA, Ratner RE, Han J, et al. Effects ofexenatide  (exendin-4) on glycemic control and weight over 30 weeks  in metformin-treated patients with type 2 diabetes. Diabe-  tes Care. 2005;28:1092-1100.  5. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of  exenatide (exendin-4) on glycemic control over 30 weeks